Lionel Tarassenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lionel Tarassenko has a total of 335 co-authors. Here are the top co-authors by number of shared publications:
- Peter James Watkinson
Nuffield Department of Clinical Neurosciences University of Oxford Oxford UK
30 shared publications - Carmelo Velardo
Sensyne Health, plc, Oxford, United Kingdom
23 shared publications - Andrew Farmer
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom
22 shared publications - Sarah Vollam
Nuffield Department of Clinical Neurosciences University of Oxford Oxford UK
21 shared publications - Cristian Roman
NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom
15 shared publications - Carlos Areia
6th Briset street, Digital Science (United Kingdom), London, United Kingdom
13 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 14, e109596
Correction: Clinical Evaluation of a Real-Time Wearable System for Monitoring In-Hospital Ambulatory Patients With COVID-19: Retrospective Data Study
[This corrects the article DOI: 10.2196/81304.].
- 22 October 2026
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 14, e109596
Open AccessCorrection: Clinical Evaluation of a Real-Time Wearable System for Monitoring In-Hospital Ambulatory Patients With COVID-19: Retrospective Data Study
[This corrects the article DOI: 10.2196/81304.].
- Open Access
- 25 September 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e84233
Remote Vital Sign Monitoring in Acutely Unwell Hospital at Home Patients: Nonrandomized Feasibility Study
Background: Remote vital sign monitoring of acute hospital at home (aHAH) patients is recommended in policy without clear guidance on implementation. While such monitoring has the potential to improve patient care, there is limited evidence for its feasibility and acceptability. Objective: This study aimed to evaluate the feasibility and acceptability of using a remote, community-based monitoring system using a vital sign wearable patch and pulse oximeter in aHAH patients. Methods: In this nonrandomized feasibility study, we recruited patients from an aHAH service in Oxford, United Kingdom, between January and October 2024. Eligible patients were aged 18 years and older with an acute illness (lower respiratory tract infection, cellulitis, urinary tract infection, systemic evidence of acute infection, acute kidney injury, or heart failure with acute fluid overload) requiring aHAH care. Pregnant women and those with contraindications to monitoring were excluded. Participants were asked to wear a chest patch to estimate their heart rate and respiratory rate (passive monitoring), and to intermittently check their oxygen saturations, blood pressure, and temperature (active monitoring). Participants were asked to complete a Technology Acceptance Questionnaire. All aHAH patients were screened. Recruitment was nonconsecutive due to the availability of the research team. Participants were monitored for 7 days or until discharge from the aHAH service, whichever was shorter. Fixed time windows were used to assess real-time vital sign data coverage during each participant’s monitoring period. The primary outcomes were the proportion of 4-hour monitoring windows with a recorded heart rate and 12-hour daytime windows with a recorded oxygen saturation level. Time-series analyses and descriptive statistics were used for quantitative data. Content analysis was used to analyze the open-ended comments in the questionnaire. Results: In total, 29 participants were recruited and 3 immediately withdrew from the study. Participants were monitored for 4.8 (IQR 2.9-6.2) days on average. Overall, 89% (600/674) of the 4-hour monitoring windows had a heart rate and 75.4% (508/674) had a respiratory rate recorded in real-time. For the 12-hour daytime windows, 58.1% (75/129) had an oxygen saturation, 54.3% (70/129) had a blood pressure, and 51.2% (66/129) had a temperature recorded. Data coverage was higher for passive monitoring compared to active monitoring. Most participants who had capacity found the combined monitoring system easy to use and thought it was useful for their health care. Conclusions: Remote monitoring of vital signs in aHAH patients is feasible. Good data coverage was achieved for the passive monitoring, which did not require specific actions by the participants or their caregivers. Further work is required to ascertain which patients would benefit most from this monitoring.
- 25 September 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10, e84233
Open AccessRemote Vital Sign Monitoring in Acutely Unwell Hospital at Home Patients: Nonrandomized Feasibility Study
Background: Remote vital sign monitoring of acute hospital at home (aHAH) patients is recommended in policy without clear guidance on implementation. While such monitoring has the potential to improve patient care, there is limited evidence for its feasibility and acceptability. Objective: This study aimed to evaluate the feasibility and acceptability of using a remote, community-based monitoring system using a vital sign wearable patch and pulse oximeter in aHAH patients. Methods: In this nonrandomized feasibility study, we recruited patients from an aHAH service in Oxford, United Kingdom, between January and October 2024. Eligible patients were aged 18 years and older with an acute illness (lower respiratory tract infection, cellulitis, urinary tract infection, systemic evidence of acute infection, acute kidney injury, or heart failure with acute fluid overload) requiring aHAH care. Pregnant women and those with contraindications to monitoring were excluded. Participants were asked to wear a chest patch to estimate their heart rate and respiratory rate (passive monitoring), and to intermittently check their oxygen saturations, blood pressure, and temperature (active monitoring). Participants were asked to complete a Technology Acceptance Questionnaire. All aHAH patients were screened. Recruitment was nonconsecutive due to the availability of the research team. Participants were monitored for 7 days or until discharge from the aHAH service, whichever was shorter. Fixed time windows were used to assess real-time vital sign data coverage during each participant’s monitoring period. The primary outcomes were the proportion of 4-hour monitoring windows with a recorded heart rate and 12-hour daytime windows with a recorded oxygen saturation level. Time-series analyses and descriptive statistics were used for quantitative data. Content analysis was used to analyze the open-ended comments in the questionnaire. Results: In total, 29 participants were recruited and 3 immediately withdrew from the study. Participants were monitored for 4.8 (IQR 2.9-6.2) days on average. Overall, 89% (600/674) of the 4-hour monitoring windows had a heart rate and 75.4% (508/674) had a respiratory rate recorded in real-time. For the 12-hour daytime windows, 58.1% (75/129) had an oxygen saturation, 54.3% (70/129) had a blood pressure, and 51.2% (66/129) had a temperature recorded. Data coverage was higher for passive monitoring compared to active monitoring. Most participants who had capacity found the combined monitoring system easy to use and thought it was useful for their health care. Conclusions: Remote monitoring of vital signs in aHAH patients is feasible. Good data coverage was achieved for the passive monitoring, which did not require specific actions by the participants or their caregivers. Further work is required to ascertain which patients would benefit most from this monitoring.
- Open Access
- 17 August 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Correction: Clinical Evaluation of a Real-Time Wearable System for Monitoring In-Hospital Ambulatory Patients With COVID-19: Retrospective Data Study (Preprint)
UNSTRUCTURED No abstract required
- 17 August 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessCorrection: Clinical Evaluation of a Real-Time Wearable System for Monitoring In-Hospital Ambulatory Patients With COVID-19: Retrospective Data Study (Preprint)
UNSTRUCTURED No abstract required
- Open Access
- 4 August 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Self-management of blood pressure following hypertensive pregnancy (the SNAP2 trial): a prospective, multi-centre, unblinded, randomised controlled trial protocol
Background: Hypertensive disorders of pregnancy affect around 10% of pregnant women and can continue following childbirth. Such hypertension that persists postnatally can be unpredictable and may have long-term health consequences but care can be sub-optimal with poor support as women transition from maternity to community services. However, there is little evidence to guide best practice for managing postnatal hypertension, and these gaps in evidence and care disproportionately affect women from minoritised ethnic and socioeconomically disadvantaged backgrounds. Previous work suggests self-management where women self-monitor blood pressure (BP) and self-titrate medication, overseen by clinicians, could improve BP control in the short and long term but has been limited to single geographical areas. The aim of the SNAP2 trial is to evaluate the clinical and cost effectiveness of a self-management intervention at scale. Methods: SNAP2 is a multi-centre unblinded randomised controlled trial. A planned sample of at least 628 participants across England with any pregnancy hypertension will be randomised within 7 days post birth to a digitally-supported self-management intervention, including self-monitoring of BP and clinician-guided titration of anti-hypertensive medication, or usual care. A cross-cutting theme is evaluating how health equity can best be ensured in postnatal hypertension management. The primary outcome is the difference in mean daytime ambulatory diastolic BP between intervention and usual care, measured between 22 to 39 weeks postpartum. Secondary outcomes include other measures of BP, maternal quality-of-life, medication adherence, adverse outcomes and readmission to hospital up to one year after birth. A qualitative process evaluation will explore how the intervention is implemented and integrated into women’s lives and clinical pathways. An economic analysis will evaluate within-trial cost and outcomes and long-term economic modelling. Discussion: The SNAP2 trial will provide essential data on the clinical and cost-effectiveness of a self-management intervention that, if proven effective, could improve current sub-optimal postnatal care for BP management. In-depth qualitative and equity data will provide important insight to inform potential implementation. Throughout the manuscript, in our references to women, we encompass all birthing people. Clinical trail number: https://doi.org/10.1186/ISRCTN11042045 .
- 4 August 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Open AccessSelf-management of blood pressure following hypertensive pregnancy (the SNAP2 trial): a prospective, multi-centre, unblinded, randomised controlled trial protocol
Background: Hypertensive disorders of pregnancy affect around 10% of pregnant women and can continue following childbirth. Such hypertension that persists postnatally can be unpredictable and may have long-term health consequences but care can be sub-optimal with poor support as women transition from maternity to community services. However, there is little evidence to guide best practice for managing postnatal hypertension, and these gaps in evidence and care disproportionately affect women from minoritised ethnic and socioeconomically disadvantaged backgrounds. Previous work suggests self-management where women self-monitor blood pressure (BP) and self-titrate medication, overseen by clinicians, could improve BP control in the short and long term but has been limited to single geographical areas. The aim of the SNAP2 trial is to evaluate the clinical and cost effectiveness of a self-management intervention at scale. Methods: SNAP2 is a multi-centre unblinded randomised controlled trial. A planned sample of at least 628 participants across England with any pregnancy hypertension will be randomised within 7 days post birth to a digitally-supported self-management intervention, including self-monitoring of BP and clinician-guided titration of anti-hypertensive medication, or usual care. A cross-cutting theme is evaluating how health equity can best be ensured in postnatal hypertension management. The primary outcome is the difference in mean daytime ambulatory diastolic BP between intervention and usual care, measured between 22 to 39 weeks postpartum. Secondary outcomes include other measures of BP, maternal quality-of-life, medication adherence, adverse outcomes and readmission to hospital up to one year after birth. A qualitative process evaluation will explore how the intervention is implemented and integrated into women’s lives and clinical pathways. An economic analysis will evaluate within-trial cost and outcomes and long-term economic modelling. Discussion: The SNAP2 trial will provide essential data on the clinical and cost-effectiveness of a self-management intervention that, if proven effective, could improve current sub-optimal postnatal care for BP management. In-depth qualitative and equity data will provide important insight to inform potential implementation. Throughout the manuscript, in our references to women, we encompass all birthing people. Clinical trail number: https://doi.org/10.1186/ISRCTN11042045 .
- Open Access
- 22 June 2026
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 14 (1) , e81304
Clinical Evaluation of a Real-Time Wearable System for Monitoring In-Hospital Ambulatory Patients With COVID-19: Retrospective Data Study
Background: Many studies have evaluated the use of wearable monitoring systems to improve patient safety in hospital. Although some have demonstrated effects on intensive care admissions, there remains little evidence of impact on patient outcomes such as mortality, hospital length of stay, and time to antibiotic administration. Very few studies have focused on how wearable monitoring systems are used in clinical practice, including how the rate of manual vital sign measurements (MVSMs) is affected. Objective: Our primary aim was to describe the physiological pattern of vital signs in hospitalized patients treated for COVID-19 outside of critical care. We also report an exploratory post hoc analysis of the impact of displaying wearable monitoring system data on the frequency of intermittent MVSMs. Methods: We conducted a retrospective study during the COVID-19 pandemic following deployment of a wearable monitoring system that continuously displayed heart rate, respiratory rate, and oxygen saturation levels. We included patients treated for COVID-19 in 3 isolation wards in a large UK hospital. Wearable monitoring system data were displayed on a dashboard in the center of each ward. We analyzed the patterns of vital signs in patients monitored using the wearable monitoring system. We compared the time to next observation (led by nursing staff) for routinely collected MVSMs between periods when patients were continuously monitored and those when they were not. In exploratory post hoc analysis, we tested whether the difference varied between stable (early warning score [EWS] above the escalation threshold) and unstable patients. Results: Patients (N=144) had continuous vital signs above the EWS threshold for escalation for 32.7% (2133/6528) of time monitored. The unadjusted median time between MVSMs for continuously monitored periods was 39 minutes (95% CI 29-49; P<.001) longer than for unmonitored periods. When adjusted for EWS category and participant-level clustering, the effect was attenuated but remained significant (14.6 minutes; P<.001). In exploratory post hoc analysis, we found that increases were larger during stable observation periods (51 minutes, 95% CI 39-62; P<.001) than during unstable periods (16 minutes, 95% CI 8-24; P<.001). However, adjusted analyses did not support a significant difference between stable and unstable periods. Conclusions: Patients in this study were at elevated risk of deterioration, spending a third of monitored time at or above the escalation threshold. We found that, by offering additional vital sign data between manual measurements, the time between routine MVSMs increased, which may reflect changes in nursing task prioritization. Although patient safety outcomes were not directly measured, we found no indication that reducing observation frequency adversely affected patient safety.
- 22 June 2026
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 14 (1) , e81304
Open AccessClinical Evaluation of a Real-Time Wearable System for Monitoring In-Hospital Ambulatory Patients With COVID-19: Retrospective Data Study
Background: Many studies have evaluated the use of wearable monitoring systems to improve patient safety in hospital. Although some have demonstrated effects on intensive care admissions, there remains little evidence of impact on patient outcomes such as mortality, hospital length of stay, and time to antibiotic administration. Very few studies have focused on how wearable monitoring systems are used in clinical practice, including how the rate of manual vital sign measurements (MVSMs) is affected. Objective: Our primary aim was to describe the physiological pattern of vital signs in hospitalized patients treated for COVID-19 outside of critical care. We also report an exploratory post hoc analysis of the impact of displaying wearable monitoring system data on the frequency of intermittent MVSMs. Methods: We conducted a retrospective study during the COVID-19 pandemic following deployment of a wearable monitoring system that continuously displayed heart rate, respiratory rate, and oxygen saturation levels. We included patients treated for COVID-19 in 3 isolation wards in a large UK hospital. Wearable monitoring system data were displayed on a dashboard in the center of each ward. We analyzed the patterns of vital signs in patients monitored using the wearable monitoring system. We compared the time to next observation (led by nursing staff) for routinely collected MVSMs between periods when patients were continuously monitored and those when they were not. In exploratory post hoc analysis, we tested whether the difference varied between stable (early warning score [EWS] above the escalation threshold) and unstable patients. Results: Patients (N=144) had continuous vital signs above the EWS threshold for escalation for 32.7% (2133/6528) of time monitored. The unadjusted median time between MVSMs for continuously monitored periods was 39 minutes (95% CI 29-49; P<.001) longer than for unmonitored periods. When adjusted for EWS category and participant-level clustering, the effect was attenuated but remained significant (14.6 minutes; P<.001). In exploratory post hoc analysis, we found that increases were larger during stable observation periods (51 minutes, 95% CI 39-62; P<.001) than during unstable periods (16 minutes, 95% CI 8-24; P<.001). However, adjusted analyses did not support a significant difference between stable and unstable periods. Conclusions: Patients in this study were at elevated risk of deterioration, spending a third of monitored time at or above the escalation threshold. We found that, by offering additional vital sign data between manual measurements, the time between routine MVSMs increased, which may reflect changes in nursing task prioritization. Although patient safety outcomes were not directly measured, we found no indication that reducing observation frequency adversely affected patient safety.
- Open Access
Insights from nine nights of self-applied, low-density sleep EEG during sleep restriction therapy: a proof-of-concept evaluation
Objectives: Self-applied, low-density EEG offers opportunities to examine sleep in the home environment, yet its feasibility during behavioural sleep interventions remains unexplored. This pilot study aimed to evaluate the feasibility and acceptability of a self-applied, low-density EEG device during sleep restriction therapy (SRT) and explore effects on sleep and affect. Methods: Seventeen adults with insomnia and depressive symptoms completed a 2-week baseline and 4 weeks of SRT. The primary outcome was the proportion of expected EEG recordings completed and scoreable. Secondary outcomes included clinical measures, sleep continuity (sleep diary, actigraphy), sleep architecture (low-density EEG for 9 nights), power spectral density, and affect. Data were analysed with linear mixed models. Cohen's d and 95% confidence intervals were reported. Results: Feasibility was demonstrated (92% of expected EEG nights completed). SRT was associated with reductions in insomnia severity, depressive symptoms, negative affect, and increases in positive affect. Robust improvements were observed across treatment in sleep continuity (SOL, WASO, SE) from diary, which were paralleled by actigraphy. EEG revealed reduced TIB, TST, N1, N2, REM sleep, and REM latency during week one. Reductions in EEG-derived TIB and N1 sleep were maintained at night 28. There were no reliable differences for spectral or spindle measures. Conclusions: These findings suggest that self-applied, low-density EEG during SRT is feasible, acceptable, and may capture sleep changes during treatment. They highlight the potential for multi-night monitoring of sleep interventions at home and elucidating mechanisms underlying therapeutic change.
Open AccessInsights from nine nights of self-applied, low-density sleep EEG during sleep restriction therapy: a proof-of-concept evaluation
Objectives: Self-applied, low-density EEG offers opportunities to examine sleep in the home environment, yet its feasibility during behavioural sleep interventions remains unexplored. This pilot study aimed to evaluate the feasibility and acceptability of a self-applied, low-density EEG device during sleep restriction therapy (SRT) and explore effects on sleep and affect. Methods: Seventeen adults with insomnia and depressive symptoms completed a 2-week baseline and 4 weeks of SRT. The primary outcome was the proportion of expected EEG recordings completed and scoreable. Secondary outcomes included clinical measures, sleep continuity (sleep diary, actigraphy), sleep architecture (low-density EEG for 9 nights), power spectral density, and affect. Data were analysed with linear mixed models. Cohen's d and 95% confidence intervals were reported. Results: Feasibility was demonstrated (92% of expected EEG nights completed). SRT was associated with reductions in insomnia severity, depressive symptoms, negative affect, and increases in positive affect. Robust improvements were observed across treatment in sleep continuity (SOL, WASO, SE) from diary, which were paralleled by actigraphy. EEG revealed reduced TIB, TST, N1, N2, REM sleep, and REM latency during week one. Reductions in EEG-derived TIB and N1 sleep were maintained at night 28. There were no reliable differences for spectral or spindle measures. Conclusions: These findings suggest that self-applied, low-density EEG during SRT is feasible, acceptable, and may capture sleep changes during treatment. They highlight the potential for multi-night monitoring of sleep interventions at home and elucidating mechanisms underlying therapeutic change.
- Open Access
Identifying clinician perceived priorities for a real-time wearable system for in-hospital monitoring: findings and evolutions following the COVID-19 pandemic
A Wearable Monitoring System (WMS), comprising a chest patch, wrist-worn pulse oximeter, and arm-worn blood pressure device, was developed in preparation for a pilot Randomised Controlled Trial (RCT) on a UK surgical ward. The system was designed to support continuous physiological monitoring and early detection of deterioration. An initial prototype user interface was developed by the research team based on prior clinical experience and engineering knowledge. To ensure suitability for clinical practice, iterative user-centred refinement was undertaken through a series of clinician focus groups and wearability assessments. Six focus groups were conducted between November 2019 and May 2021 involving multidisciplinary healthcare professionals. Feedback from these sessions informed successive interface and system modifications. System development spanned the COVID-19 pandemic, during which the WMS was rapidly adapted and deployed to support clinical care on isolation wards. Feedback obtained during this period was incorporated into later versions of the system and provided a unique opportunity to examine changes in clinician priorities under pandemic conditions. Clinicians consistently prioritised alert visibility, alarm fatigue mitigation, parameter flexibility, and centralised monitoring. Notably, preferences regarding alert modality and access mechanisms evolved over time: early enthusiasm for mobile or smartphone-type devices shifted towards a preference for fixed, ward-based displays and audible alerts at the nurses’ station following pandemic deployment. Building on previous wearability testing in healthy volunteers, wearability testing using a validated questionnaire was completed by 169 patient participants during the RCT. The chest patch and pulse oximeter demonstrated high tolerability, whereas the blood pressure cuff showed poor wearability and was removed from the final system. These findings demonstrate the importance of iterative, clinician-led design for wearable WMS and highlight how extreme clinical contexts such as the COVID-19 pandemic can significantly reshape perceived requirements for safety-critical monitoring technologies.
Open AccessIdentifying clinician perceived priorities for a real-time wearable system for in-hospital monitoring: findings and evolutions following the COVID-19 pandemic
A Wearable Monitoring System (WMS), comprising a chest patch, wrist-worn pulse oximeter, and arm-worn blood pressure device, was developed in preparation for a pilot Randomised Controlled Trial (RCT) on a UK surgical ward. The system was designed to support continuous physiological monitoring and early detection of deterioration. An initial prototype user interface was developed by the research team based on prior clinical experience and engineering knowledge. To ensure suitability for clinical practice, iterative user-centred refinement was undertaken through a series of clinician focus groups and wearability assessments. Six focus groups were conducted between November 2019 and May 2021 involving multidisciplinary healthcare professionals. Feedback from these sessions informed successive interface and system modifications. System development spanned the COVID-19 pandemic, during which the WMS was rapidly adapted and deployed to support clinical care on isolation wards. Feedback obtained during this period was incorporated into later versions of the system and provided a unique opportunity to examine changes in clinician priorities under pandemic conditions. Clinicians consistently prioritised alert visibility, alarm fatigue mitigation, parameter flexibility, and centralised monitoring. Notably, preferences regarding alert modality and access mechanisms evolved over time: early enthusiasm for mobile or smartphone-type devices shifted towards a preference for fixed, ward-based displays and audible alerts at the nurses’ station following pandemic deployment. Building on previous wearability testing in healthy volunteers, wearability testing using a validated questionnaire was completed by 169 patient participants during the RCT. The chest patch and pulse oximeter demonstrated high tolerability, whereas the blood pressure cuff showed poor wearability and was removed from the final system. These findings demonstrate the importance of iterative, clinician-led design for wearable WMS and highlight how extreme clinical contexts such as the COVID-19 pandemic can significantly reshape perceived requirements for safety-critical monitoring technologies.
- Open Access
- 1 March 2026
- Published by National Institute for Health and Care Research in Programme Grants for Applied Research
- p. 1-50
Optimising the monitoring and management of raised blood pressure including proteinuria testing during pregnancy: the BUMP research programme including 2 RCTs
Background: Raised blood pressure affects 10% of pregnancies worldwide, of which around half develop pre-eclampsia including proteinuria, causing maternal and perinatal morbidity and mortality. Objectives: To develop and test interventions for self-monitoring of blood pressure designed to improve the detection and management of hypertension in pregnancy. Additionally, to test the accuracy of self-testing of urine for protein, a key marker of pre-eclampsia. Design and methods: Development phase, a pilot trial, two large randomised controlled trials of self-monitoring of blood pressure interventions with integrated economic evaluations, linked qualitative work, a large survey and a diagnostic accuracy study of self-testing for proteinuria, and finally economic modelling. Setting and participants: Antenatal clinics in 16 English hospitals. Participants were pregnant women and antenatal healthcare professionals. Patient and public involvement: Comprehensive involvement from initial development through to dissemination, with collaboration from both individuals and relevant charities and organisations. Interventions: Self-monitoring of blood pressure supported by app to improve the detection (BUMP1) and management (BUMP2) of raised blood pressure in pregnancy (WS3.2.1 and 2). Proteinuria self-testing by pregnant hypertensive women (UDIP, WS4). Main outcome measures: Qualitative data informed the development of the BUMP App and trial (WS1). Feasibility of self-monitoring of blood pressure in hypertensive pregnancy (recruitment, retention, adherence and intervention persistence) (WS2). Prevalence of self-monitoring of blood pressure during pregnancy (WS3.1). Time to diagnosis of hypertension defined in routinely recorded clinical data (BUMP1, WS3.2.1) and difference in mean systolic blood pressure recorded by healthcare professionals between randomisation and birth (BUMP2, WS3.2.2). WS3.3 and 4.2 evaluated experiences with the trial and UDIP respectively using inductive and deductive thematic analysis. Within-trial cost–consequence analysis and long-term cost-effectiveness modelling (WS3.4 and WS5). Proteinuria testing accuracy (WS4.1). Results: WS1 : Areas important to staff included providing clear patient information and supporting them in decision-making in the context of discrepant readings. The intervention was optimised iteratively with pregnant women. WS2 : A feasibility trial showed that the self-monitoring of blood pressure intervention was feasible and acceptable. WS3.1 : Data from a survey of 5181 women showed that 19% of pregnant women were currently self-monitoring blood pressure but only 482/983 (49%) shared this information with healthcare professionals. WS3.2.1 : Self-monitoring of blood pressure in addition to usual care did not lead to an earlier diagnosis of clinic hypertension in routinely recorded clinical data with no evidence of differences in maternal or perinatal outcomes or serious adverse events (BUMP1). WS3.2.2: Self-monitoring of blood pressure in pregnancy hypertension did not improve clinic blood pressure control, with no difference in maternal or perinatal outcomes or serious adverse events (BUMP2). WS3.3: Self-monitoring was generally accepted by women and professionals with differences in views of which blood pressure data to give precedence. Women found self-monitoring empowering, provided health professionals considered home readings in their management. On occasion self-monitoring proved unsettling due to uncertainty. WS3.4: Within trial economic analyses revealed no significant difference in overall total costs between trial arms in either BUMP1 or BUMP2. Women’s health-related quality of life (EQ-5D-5L) was similar between groups in both trials. WS4 : Self-testing for proteinuria had a sensitivity of 0.71 (95% confidence interval 0.62 to 0.79) and a specificity of 0.89 (95% confidence interval 0.84 to 0.92) compared to laboratory protein–creatinine ratio testing and this was not clinically or statistically different when compared to healthcare professionals or a colorimetric monitor (UDIP, WS4.1). Self-testing was generally acceptable (WS4.2). WS5 : Model frameworks capable of facilitating exploration of the long-term cost-effectiveness of combining self-monitoring of blood pressure with blood pressure treatment and management policies were developed for use in future research projects in the area. Implementation : Self-monitoring was rapidly and widely implemented during the pandemic but has yet to become fully embedded in clinical pathways. Limitations: Self-monitoring of blood pressure by women in the control groups; difficulties in testing self-monitoring of blood pressure in clinical pathways in the absence of evidence or accepted treatment thresholds; process evaluation suggested women and professionals privileged different information. Conclusions: Self-monitoring of blood pressure during higher risk or hypertensive pregnancy was feasible, acceptable, safe, and no more expensive, but did not improve the detection of hypertension or blood pressure control in those with hypertension when used alongside usual care. During the programme, self-monitoring of blood pressure entered common practice in pregnancy, a process accelerated by the pandemic. Pregnant women can read a dipstick for urinary protein with similar accuracy to healthcare professionals or colorimetric testing, and find this acceptable, suggesting that self-testing could be included in clinical pathways. Future work: Future trials of interventions including self-monitoring of blood pressure should test strategies in the context of novel clinical pathways. Study registration: This study is registered as Current Controlled Trials ISRCTN16018898. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research programme (NIHR award ref.: RP-PG-0614-20005) and is published in full in Programme Grants for Applied Research ; Vol. 14, No. 3. See the NIHR Funding and Awards website for further award information.
- 1 March 2026
- Published by National Institute for Health and Care Research in Programme Grants for Applied Research
- p. 1-50
Open AccessOptimising the monitoring and management of raised blood pressure including proteinuria testing during pregnancy: the BUMP research programme including 2 RCTs
Background: Raised blood pressure affects 10% of pregnancies worldwide, of which around half develop pre-eclampsia including proteinuria, causing maternal and perinatal morbidity and mortality. Objectives: To develop and test interventions for self-monitoring of blood pressure designed to improve the detection and management of hypertension in pregnancy. Additionally, to test the accuracy of self-testing of urine for protein, a key marker of pre-eclampsia. Design and methods: Development phase, a pilot trial, two large randomised controlled trials of self-monitoring of blood pressure interventions with integrated economic evaluations, linked qualitative work, a large survey and a diagnostic accuracy study of self-testing for proteinuria, and finally economic modelling. Setting and participants: Antenatal clinics in 16 English hospitals. Participants were pregnant women and antenatal healthcare professionals. Patient and public involvement: Comprehensive involvement from initial development through to dissemination, with collaboration from both individuals and relevant charities and organisations. Interventions: Self-monitoring of blood pressure supported by app to improve the detection (BUMP1) and management (BUMP2) of raised blood pressure in pregnancy (WS3.2.1 and 2). Proteinuria self-testing by pregnant hypertensive women (UDIP, WS4). Main outcome measures: Qualitative data informed the development of the BUMP App and trial (WS1). Feasibility of self-monitoring of blood pressure in hypertensive pregnancy (recruitment, retention, adherence and intervention persistence) (WS2). Prevalence of self-monitoring of blood pressure during pregnancy (WS3.1). Time to diagnosis of hypertension defined in routinely recorded clinical data (BUMP1, WS3.2.1) and difference in mean systolic blood pressure recorded by healthcare professionals between randomisation and birth (BUMP2, WS3.2.2). WS3.3 and 4.2 evaluated experiences with the trial and UDIP respectively using inductive and deductive thematic analysis. Within-trial cost–consequence analysis and long-term cost-effectiveness modelling (WS3.4 and WS5). Proteinuria testing accuracy (WS4.1). Results: WS1 : Areas important to staff included providing clear patient information and supporting them in decision-making in the context of discrepant readings. The intervention was optimised iteratively with pregnant women. WS2 : A feasibility trial showed that the self-monitoring of blood pressure intervention was feasible and acceptable. WS3.1 : Data from a survey of 5181 women showed that 19% of pregnant women were currently self-monitoring blood pressure but only 482/983 (49%) shared this information with healthcare professionals. WS3.2.1 : Self-monitoring of blood pressure in addition to usual care did not lead to an earlier diagnosis of clinic hypertension in routinely recorded clinical data with no evidence of differences in maternal or perinatal outcomes or serious adverse events (BUMP1). WS3.2.2: Self-monitoring of blood pressure in pregnancy hypertension did not improve clinic blood pressure control, with no difference in maternal or perinatal outcomes or serious adverse events (BUMP2). WS3.3: Self-monitoring was generally accepted by women and professionals with differences in views of which blood pressure data to give precedence. Women found self-monitoring empowering, provided health professionals considered home readings in their management. On occasion self-monitoring proved unsettling due to uncertainty. WS3.4: Within trial economic analyses revealed no significant difference in overall total costs between trial arms in either BUMP1 or BUMP2. Women’s health-related quality of life (EQ-5D-5L) was similar between groups in both trials. WS4 : Self-testing for proteinuria had a sensitivity of 0.71 (95% confidence interval 0.62 to 0.79) and a specificity of 0.89 (95% confidence interval 0.84 to 0.92) compared to laboratory protein–creatinine ratio testing and this was not clinically or statistically different when compared to healthcare professionals or a colorimetric monitor (UDIP, WS4.1). Self-testing was generally acceptable (WS4.2). WS5 : Model frameworks capable of facilitating exploration of the long-term cost-effectiveness of combining self-monitoring of blood pressure with blood pressure treatment and management policies were developed for use in future research projects in the area. Implementation : Self-monitoring was rapidly and widely implemented during the pandemic but has yet to become fully embedded in clinical pathways. Limitations: Self-monitoring of blood pressure by women in the control groups; difficulties in testing self-monitoring of blood pressure in clinical pathways in the absence of evidence or accepted treatment thresholds; process evaluation suggested women and professionals privileged different information. Conclusions: Self-monitoring of blood pressure during higher risk or hypertensive pregnancy was feasible, acceptable, safe, and no more expensive, but did not improve the detection of hypertension or blood pressure control in those with hypertension when used alongside usual care. During the programme, self-monitoring of blood pressure entered common practice in pregnancy, a process accelerated by the pandemic. Pregnant women can read a dipstick for urinary protein with similar accuracy to healthcare professionals or colorimetric testing, and find this acceptable, suggesting that self-testing could be included in clinical pathways. Future work: Future trials of interventions including self-monitoring of blood pressure should test strategies in the context of novel clinical pathways. Study registration: This study is registered as Current Controlled Trials ISRCTN16018898. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research programme (NIHR award ref.: RP-PG-0614-20005) and is published in full in Programme Grants for Applied Research ; Vol. 14, No. 3. See the NIHR Funding and Awards website for further award information.
- Open Access
Screening for hypertension in the inpatient environment (SHINE): a prospective diagnostic accuracy study among adult hospital patients
Background: Hypertension is the leading risk factor for death globally. Undiagnosed hypertension is common, but the incidence in hospitalised patients is unclear. There are calls for universal facility-based screening for hypertension among all attending patients. The hospital inpatient setting, where blood pressure (BP) is measured routinely and repeatedly, presents an ideal opportunity. However, international hypertension guidelines do not include inpatient BP thresholds for diagnostic or treatment purposes. We investigated the performance of current UK community BP thresholds for diagnosing hypertension in the hospital setting. Objectives: Investigate the diagnostic performance of the current UK ambulatory BP diagnostic thresholds for systolic and diastolic hypertension in the hospital setting against the reference test of community-based ambulatory BP monitoring (ABPM). Design: A prospective diagnostic accuracy study. Setting: Hospital inpatients admitted to three UK centres were approached. Follow-up ABPM was delivered in the community. Participants: Eligible patients were aged between 18 and 80 years, with no prior diagnosis of, or prescription for hypertension, and whose mean cumulative daytime BP was 120 mm Hg to 179 mm Hg systolic and ≤109 mm Hg diastolic from the 24th hour of their hospital admission. Interventions: Participants received 24-hour ABPM 4–26 weeks post-discharge, as the reference test for hypertension, with UK diagnostic thresholds of an average daytime BP of ≥135 mm Hg systolic and ≥85 mm Hg diastolic applied. Participants found to be severely hypertensive at the ABPM fitting appointment were also considered reference-test positive but did not proceed with ABPM. Primary and secondary outcome measures: The diagnostic performance of a mean daytime in-hospital BP of ≥135 mm Hg systolic or ≥85 mm Hg diastolic (index test) for the prediction of hypertension diagnosed on ABPM (reference test) was assessed using sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) as primary outcome measures. Additionally, we explored the accuracy of a range of alternative in-hospital systolic and diastolic BP thresholds against the same reference test. Results: 351 participants were enrolled and 206 completed the study protocol. The average age of the 206 participants was 53 years, 55% were male, and 91 (44%) had daytime community hypertension on ABPM reference testing. Of 107 participants with raised in-hospital daytime BP, 59 (55%) had daytime community hypertension. When assessing the performance of the index test for detecting daytime community hypertension, sensitivity was 65% (59/91, 54% to 75%) and specificity was 58% (67/115, 49% to 67%). The PPV was 55% (59/107, 45% to 65%) and NPV was 68% (67/99, 58% to 77%), respectively. A further 45/206 participants (23%) had night-time community hypertension when assessed using European diagnostic thresholds for nocturnal hypertension (120 mm Hg systolic or 70 mm Hg diastolic), while 25/107 of those with raised in-hospital daytime BP (23%) had night-time community hypertension. When assessing the performance of the index test for detecting either day or night-time community hypertension, sensitivity was 62% (84/135, 53% to 70%) and specificity was 68% (48/71, 55% to 78%). The PPV was 79% (84/107, 70% to 86%) and NPV was 48% (48/99, 38% to 59%). Conclusions: Undiagnosed hypertension is common in hospitalised patients, particularly those with raised in-hospital BP. While in-hospital BP alone is an imperfect predictor and should not be used as a stand-alone diagnostic test, this could serve as a trigger for further assessment of BP in the community after discharge. Trial registration number: The study protocol was registered with the ISCTRN Registry ( ISRCTN80586284 ).
Open AccessScreening for hypertension in the inpatient environment (SHINE): a prospective diagnostic accuracy study among adult hospital patients
Background: Hypertension is the leading risk factor for death globally. Undiagnosed hypertension is common, but the incidence in hospitalised patients is unclear. There are calls for universal facility-based screening for hypertension among all attending patients. The hospital inpatient setting, where blood pressure (BP) is measured routinely and repeatedly, presents an ideal opportunity. However, international hypertension guidelines do not include inpatient BP thresholds for diagnostic or treatment purposes. We investigated the performance of current UK community BP thresholds for diagnosing hypertension in the hospital setting. Objectives: Investigate the diagnostic performance of the current UK ambulatory BP diagnostic thresholds for systolic and diastolic hypertension in the hospital setting against the reference test of community-based ambulatory BP monitoring (ABPM). Design: A prospective diagnostic accuracy study. Setting: Hospital inpatients admitted to three UK centres were approached. Follow-up ABPM was delivered in the community. Participants: Eligible patients were aged between 18 and 80 years, with no prior diagnosis of, or prescription for hypertension, and whose mean cumulative daytime BP was 120 mm Hg to 179 mm Hg systolic and ≤109 mm Hg diastolic from the 24th hour of their hospital admission. Interventions: Participants received 24-hour ABPM 4–26 weeks post-discharge, as the reference test for hypertension, with UK diagnostic thresholds of an average daytime BP of ≥135 mm Hg systolic and ≥85 mm Hg diastolic applied. Participants found to be severely hypertensive at the ABPM fitting appointment were also considered reference-test positive but did not proceed with ABPM. Primary and secondary outcome measures: The diagnostic performance of a mean daytime in-hospital BP of ≥135 mm Hg systolic or ≥85 mm Hg diastolic (index test) for the prediction of hypertension diagnosed on ABPM (reference test) was assessed using sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) as primary outcome measures. Additionally, we explored the accuracy of a range of alternative in-hospital systolic and diastolic BP thresholds against the same reference test. Results: 351 participants were enrolled and 206 completed the study protocol. The average age of the 206 participants was 53 years, 55% were male, and 91 (44%) had daytime community hypertension on ABPM reference testing. Of 107 participants with raised in-hospital daytime BP, 59 (55%) had daytime community hypertension. When assessing the performance of the index test for detecting daytime community hypertension, sensitivity was 65% (59/91, 54% to 75%) and specificity was 58% (67/115, 49% to 67%). The PPV was 55% (59/107, 45% to 65%) and NPV was 68% (67/99, 58% to 77%), respectively. A further 45/206 participants (23%) had night-time community hypertension when assessed using European diagnostic thresholds for nocturnal hypertension (120 mm Hg systolic or 70 mm Hg diastolic), while 25/107 of those with raised in-hospital daytime BP (23%) had night-time community hypertension. When assessing the performance of the index test for detecting either day or night-time community hypertension, sensitivity was 62% (84/135, 53% to 70%) and specificity was 68% (48/71, 55% to 78%). The PPV was 79% (84/107, 70% to 86%) and NPV was 48% (48/99, 38% to 59%). Conclusions: Undiagnosed hypertension is common in hospitalised patients, particularly those with raised in-hospital BP. While in-hospital BP alone is an imperfect predictor and should not be used as a stand-alone diagnostic test, this could serve as a trigger for further assessment of BP in the community after discharge. Trial registration number: The study protocol was registered with the ISCTRN Registry ( ISRCTN80586284 ).
- Open Access
- 15 October 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27 (1) , e85415
Correction: Toward a Multivariate Prediction Model of Pharmacological Treatment for Women With Gestational Diabetes Mellitus: Algorithm Development and Validation
[This corrects the article DOI: 10.2196/21435.].
- 15 October 2025
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 27 (1) , e85415
Open AccessCorrection: Toward a Multivariate Prediction Model of Pharmacological Treatment for Women With Gestational Diabetes Mellitus: Algorithm Development and Validation
[This corrects the article DOI: 10.2196/21435.].